TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31834166

Group type: EXPERIMENTAL
Intervention: 10-week HiBalance group training (n = 61)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (n = 56)
Number of subjects: 117
Study: 31239099

Group type: EXPERIMENTAL
Intervention: Taijia (generic clopidogrel)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Plavix® (reference clopidogrel)
Number of subjects: 128
Study: 26969422

Group type: EXPERIMENTAL
Intervention: Conventional (two-piece) brackets
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metal injection moulding (MIM) brackets
Number of subjects: 46
Study: 25499208

Group type: EXPERIMENTAL
Intervention: SPORT surgical cohort
Number of subjects: 6846

Group type: COMPARATOR
Intervention: NSQIP cohort
Number of subjects: 6846

Group type: COMPARATOR
Intervention: SPORT nonoperative group
Number of subjects: 6846
Study: 22421017

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA) group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional PN support
Number of subjects: 98
Study: 20499117

Group type: EXPERIMENTAL
Intervention: Galvano-formed crowns (GC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Metal-ceramic crowns (MC)
Number of subjects: 48
Study: 19074978

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment focusing solely on eating disorder features
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Complex cognitive-behavioral treatment addressing mood intolerance, clinical perfectionism, low self-esteem, or interpersonal difficulties
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waiting list control condition (8-week period before treatment)
Number of subjects: 154
Study: 16719653

Group type: EXPERIMENTAL
Intervention: Proactive interference (PI) adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commonly used measures of judgment accuracy (absolute and relative accuracy)
Number of subjects: 0
Study: 15532005

Group type: EXPERIMENTAL
Intervention: Music (trance, tempo = 142 beats/min, volume = 87 dB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Music (trance)
Number of subjects: 16
Study: 11286443

Group type: EXPERIMENTAL
Intervention: Various treatments for cluster headaches; specific interventions not detailed; no dosage or duration mentioned.
Number of subjects: 0
Study: 9258477

Group type: EXPERIMENTAL
Intervention: Deployment time of 5 min
Number of subjects: 140

Group type: COMPARATOR
Intervention: Deployment time of 30 min
Number of subjects: 140
Study: 8280555

Group type: EXPERIMENTAL
Intervention: 5 cm H2O CPAP with air
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 5 cm H2O CPAP with 100% oxygen
Number of subjects: 61

Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 61
Study: 3816081

Group type: EXPERIMENTAL
Intervention: Ethanol consumption
Number of subjects: 8
Study: 29766701

Group type: EXPERIMENTAL
Intervention: Topical daily application of a lotion containing N1‐methylspermidine and Sandalore
Number of subjects: 60
Study: 27090975

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS) with prostate-specific antigen tests every 3-12 months, rebiopsies in cases of clinical progression, and every 2-3 years in men with stable disease.
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 474
Study: 24281004

Group type: EXPERIMENTAL
Intervention: Dose-escalated weekly paclitaxel (80-120 mg/m²)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-dose weekly paclitaxel (80 mg/m²)
Number of subjects: 90
Study: 22322126

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine (CHX) solution applied to the umbilical cord at birth and once daily for up to 14 days along with soap and educational messages promoting handwashing.
Number of subjects: 9741

Group type: EXPERIMENTAL
Intervention: Handwashing promotion only.
Number of subjects: 9741

Group type: COMPARATOR
Intervention: Standard dry cord care (control group).
Number of subjects: 9741
Study: 20385495

Group type: EXPERIMENTAL
Intervention: Letrozole (B+C; N=65)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tamoxifen (A+D; N=55)
Number of subjects: 120
Study: 18939344

Group type: EXPERIMENTAL
Intervention: Topical Cyclosporin A (Restasis) with intensive prednisolone acetate
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo with intensive prednisolone acetate
Number of subjects: 108
Study: 16234072

Group type: EXPERIMENTAL
Intervention: Suction elastic band ligator
Number of subjects: 100

Group type: COMPARATOR
Intervention: Forceps ligator
Number of subjects: 100
Study: 12110996

Group type: EXPERIMENTAL
Intervention: 30 mg pyridostigmine bromide (PB)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 60 mg pyridostigmine bromide (PB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: pyridostigmine bromide (PB)
Number of subjects: 67
Study: 10640206

Group type: EXPERIMENTAL
Intervention: Primary stenting (group II)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Primary angioplasty using only balloon (group I)
Number of subjects: 163
Study: 7710451

Group type: EXPERIMENTAL
Intervention: Conventional statistical methods (t-test, mean values, boxplot)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wilcoxon-Mann-Whitney test
Number of subjects: 0
Study: 2162258

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 97
Study: 385400

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 31899792

Group type: EXPERIMENTAL
Intervention: Gastric atrophy (defined as a serum level of pepsinogen I <55 μg/L)
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Gastric atrophy and poor oral health interaction
Number of subjects: 1210
Study: 31859347

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 78

Group type: COMPARATOR
Intervention: Associative focus
Number of subjects: 78
Study: 29781525

Group type: EXPERIMENTAL
Intervention: Health post intervention
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Health center intervention
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 282
Study: 26944326

Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neostigmine (50 μg/kg) plus atropine (15 μg/kg)
Number of subjects: 60
Study: 23236208

Group type: EXPERIMENTAL
Intervention: Music training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Painting training
Number of subjects: 0
Study: 22639053

Group type: COMPARATOR
Intervention: Fixed-schedule induction therapy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Individualized induction therapy
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Ubenimex
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Gender (female patients)
Number of subjects: 242
Study: 20029377

Group type: EXPERIMENTAL
Intervention: 200 g fructose daily for 2 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 74
Study: 19029205

Group type: EXPERIMENTAL
Intervention: Pravastatin (cholesterol-lowering drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 0
Study: 16155766

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 30
Study: 12211225

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate (CET/glu, dose: 10 mg peptide base)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cetrorelix acetate (CET/wat, dose: 10 mg peptide base)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate (CET/glu, dose: 5 mg peptide base)
Number of subjects: 36
Study: 10768735

Group type: EXPERIMENTAL
Intervention: Zafirlukast tablets (Accolate) 20 mg b.i.d.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate (BDP) 100 or 200 microg b.i.d.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Inhaler technique assessment
Number of subjects: 132
Study: 9041488

Group type: EXPERIMENTAL
Intervention: Personal invitation letter with a set time of appointment
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Questionnaire and instructions for self-examination of the skin
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Nurses' judgment of skin lesions
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Doctors' judgment of skin lesions
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Detection of malignant melanomas
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Nurses' screening competence
Number of subjects: 5000
Study: 1354618

Group type: EXPERIMENTAL
Intervention: Bunazosin 2.0 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 7
Study: 6084460

Group type: EXPERIMENTAL
Intervention: Iron prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31839169

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian function suppression (T + OFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (E + OFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 0
Study: 30119148

Group type: COMPARATOR
Intervention: Remifentanil–propofol (RP group, n = 40)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sufentanil–propofol (SP group, n = 43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Remifentanil–propofol (RP group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sufentanil–propofol (SP group)
Number of subjects: 83
Study: 27909164

Group type: EXPERIMENTAL
Intervention: Single-dose psilocybin (0.3 mg/kg) with psychotherapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Niacin with psychotherapy (Control)
Number of subjects: 29
Study: 24680105

Group type: EXPERIMENTAL
Intervention: Alcohol plus chlorhexidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 80
Study: 22651373

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 20536430

Group type: EXPERIMENTAL
Intervention: Ready for Child programme (9 hours of antenatal training)
Number of subjects: 1193
Study: 18538469

Group type: EXPERIMENTAL
Intervention: Degarelix 200 mg initial dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg initial dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Degarelix 160 mg monthly maintenance dose
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Degarelix (all dosages)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Degarelix treatment
Number of subjects: 187
Study: 15854217

Group type: EXPERIMENTAL
Intervention: on-line hemodiafiltration (HDF)
Number of subjects: 27

Group type: COMPARATOR
Intervention: low-flux hemodialysis (HD)
Number of subjects: 27
Study: 12442064

Group type: COMPARATOR
Intervention: Insulin twice daily (premixed combination of regular human and NPH insulin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin combined with daytime sulphonylurea (combination group)
Number of subjects: 16
Study: 10616949

Group type: EXPERIMENTAL
Intervention: Psychological therapy (individual cognitive behavioural therapy and applied relaxation)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Psychological therapy (aggregate data across types of treatment)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Psychological therapy (12 of the 20 treatment conditions)
Number of subjects: 404
Study: 7853954

Group type: EXPERIMENTAL
Intervention: Dantrolene (3 days treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with exertional rhabdomyolysis (baseline)
Number of subjects: 0
Study: 2006594

Group type: COMPARATOR
Intervention: Saline + Propofol 2.5 mg.kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1 (Control for Pain)
Number of subjects: 59
Study: 6844366

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg)/Hydrochlorothiazide (25 mg)/Amiloride (2.5 mg) preparation
Number of subjects: 558

Group type: COMPARATOR
Intervention: Full explanation for the change in therapy
Number of subjects: 558

Group type: COMPARATOR
Intervention: Simple notification of treatment change
Number of subjects: 558
Study: 31655586

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 55
Study: 30443679

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN‐α) administered subcutaneously at a dosage of 15,000 Units for three consecutive days following myocardial infarction in a rat model
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Induction of type I interferon (IFN) signalling in human monocytes
Number of subjects: 51
Study: 27374272

Group type: EXPERIMENTAL
Intervention: Elental
Number of subjects: 33

Group type: COMPARATOR
Intervention: Azulene
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 25122975

Group type: EXPERIMENTAL
Intervention: Spinbrush Truly Radiant Deep Clean (TRDC)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Spinbrush Truly Radiant Extra Whitening (TREW)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Manual Toothbrush (MT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Spinbrush Truly Radiant Deep Clean (TRDC) and Spinbrush Truly Radiant Extra Whitening (TREW)
Number of subjects: 65
Study: 18198195

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 15293420

Group type: EXPERIMENTAL
Intervention: Adhesive system applied to human enamel (H-E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive system applied to bovine enamel (B-E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive system applied to porcine enamel (P-E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive system applied to human dentin (H-D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive system applied to bovine dentin (B-D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive system applied to porcine dentin (P-D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of bond strengths between human, bovine, and porcine teeth
Number of subjects: 30
Study: 11093698

Group type: EXPERIMENTAL
Intervention: Oxygen administration during walks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Compressed air (control)
Number of subjects: 31
Study: 9351876

Group type: EXPERIMENTAL
Intervention: Immunoradiometric assay (I‐BALP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Electrophoretic techniques (E‐BALP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Total alkaline phosphatase (TALP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (60 mg every 3 weeks, administered 4 times)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Bone gla protein (BGP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Carboxyterminal propeptide of type I procollagen (PICP)
Number of subjects: 198
Study: 8214731

Group type: EXPERIMENTAL
Intervention: morphine 2 mg/fentanyl 50 micrograms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: morphine 2 mg/fentanyl 100 micrograms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: morphine 4 mg/fentanyl 50 micrograms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: morphine 4 mg/fentanyl 100 micrograms
Number of subjects: 120
Study: 2890808

Group type: EXPERIMENTAL
Intervention: Recombinant alpha-interferon
Number of subjects: 0
Study: 31414957

Group type: EXPERIMENTAL
Intervention: Acute xenon inhalation (30% FiXe for 20 min, 50% FiXe for 5 min, 70% FiXe for 2 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chronic xenon inhalation (70% FiXe for 2 min on 7 consecutive days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 4 wk of xenon inhalation (Phase II)
Number of subjects: 27
Study: 28131837

Group type: EXPERIMENTAL
Intervention: Isomerized hop extract (IHE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27465523

Group type: EXPERIMENTAL
Intervention: Pain stimulation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pain stimulation with ICU sound
Number of subjects: 18

Group type: COMPARATOR
Intervention: Negative emotions
Number of subjects: 18
Study: 25325609

Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg/day
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Armodafinil (50, 150, or 250 mg/day)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Armodafinil (open-label extension)
Number of subjects: 117
Study: 22772666

Group type: EXPERIMENTAL
Intervention: Cued category fluency task
Number of subjects: 86

Group type: COMPARATOR
Intervention: Uncued category fluency task
Number of subjects: 86
Study: 19606509

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation (AS) for 20 min at Baihui (GV 20) and 4 spirit acupoints
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation (AS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no manual twisting of needles, no qi)
Number of subjects: 30
Study: 17311944

Group type: EXPERIMENTAL
Intervention: beta-glucan muesli
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: combination muesli
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: plant stanols
Number of subjects: 40
Study: 14967379

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11527457

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM) applied to the elbow
Number of subjects: 23
Study: 9476035

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily
Number of subjects: 232
Study: 7946164

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intravenous nitroprusside (SNP)
Number of subjects: 121
Study: 3284065

Group type: EXPERIMENTAL
Intervention: Aza (2.1 mg/kg/d) plus MP (3.6 mg/kg/d tapered to 0.5 mg/kg/d by day 15)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CsA (10 mg/kg/d tapered to 8 mg/kg/d by day 28)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CsA (10 mg/kg/d tapered to 8 mg/kg/d by day 28) plus MP (3.6 mg/kg/d tapered to 0 mg/kg/d by day 9)
Number of subjects: 96
Study: 30099395

Group type: EXPERIMENTAL
Intervention: Morita Therapy plus treatment as usual (TAU)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 68
Study: 27585724

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local Anesthesia
Number of subjects: 0
Study: 24898858

Group type: EXPERIMENTAL
Intervention: Intervention group (brief, clinic-based, single-session programme)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 311
Study: 23422056

Group type: EXPERIMENTAL
Intervention: Home-based Voluntary Counselling and Testing
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Other testing approaches
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Being tested for HIV
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Home-based Voluntary Counselling and Testing vs. Other testing approaches
Number of subjects: 1500
Study: 20937107

Group type: EXPERIMENTAL
Intervention: Follicular fluid levels of progesterone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Follicular fluid levels of testosterone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Follicular fluid levels of estradiol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Granulosa cell production of progesterone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Granulosa cell production of estradiol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Granulosa cell production of testosterone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation of follicular estradiol levels with progesterone levels
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation of follicular estradiol levels with testosterone levels
Number of subjects: 35
Study: 18706103

Group type: EXPERIMENTAL
Intervention: Water-based training program with perturbation exercises (24 sessions over 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study: 16624551

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative quadrantectomy
Number of subjects: 0
Study: 12660665

Group type: EXPERIMENTAL
Intervention: Physiologic pacing (dual-chamber or atrial only)
Number of subjects: 1990

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 1990
Study: 11078174

Group type: EXPERIMENTAL
Intervention: Cortisol (oral administration for 2 or 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (oral administration for 2 or 5 days)
Number of subjects: 14
Study: 8740998

Group type: EXPERIMENTAL
Intervention: Tacrine hydrochloride (Cognex)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 1400058

Group type: EXPERIMENTAL
Intervention: 20 micrograms of intranasal DDAVP
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3839390

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2% pilocarpine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 32